Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koen van Besien

Showing results (131-140 of 241) with videos related to

Pageof 25
Sort By:
Leukemia & Lymphoma|October 14, 2009
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrenceKoen van Besien, Alexander Dew, Shang Lin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2005
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minoritiesChristopher J Schwake, Mary Eapen, Stephanie J Lee, et al.
Journal of Fungi (Basel, Switzerland)|February 7, 2020
Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant <i>Candida tropicalis</i>: An Emerging Threat to Immunocompromised Patients with Hematological MalignanciesMaroun M Sfeir, Cristina Jiménez-Ortigosa, Maria N Gamaletsou, et al.
Transplantation and Cellular Therapy|April 3, 2021
Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical ImplicationsJeffrey Kubiak, Emily Davidson, Rosemary Soave, et al.
Leukemia & Lymphoma|June 3, 2017
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>Sarah C Rutherford, Eric N Stewart, Zhengming Chen, et al.
Leukemia & Lymphoma|September 6, 2007
Successful allogeneic transplantation of patients with suspected prior invasive mold infectionBrian T Hill, Lavayna Kondapalli, Andrew Artz, et al.
Leukemia & Lymphoma|July 14, 2020
Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantationMaxwell Brown, Rza Abasov, David Salerno, et al.
Leukemia & Lymphoma|July 1, 2024
Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomesKoen van Besien, Hongtao Liu, Seunghee Margevicius, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantationAndrew S Artz, Amittha Wickrema, Shira Dinner, et al.
Cytotherapy|May 3, 2012
Influence of related donor age on outcomes after peripheral blood stem cell transplantationElie M Richa, Rangesh Kunnavakkam, Lucy A Godley, et al.
Pageof 25

Showing results (131-140 of 241) with videos related to

Sort By:
Pageof 25
Leukemia & Lymphoma|October 14, 2009
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrenceKoen van Besien, Alexander Dew, Shang Lin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2005
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minoritiesChristopher J Schwake, Mary Eapen, Stephanie J Lee, et al.
Journal of Fungi (Basel, Switzerland)|February 7, 2020
Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant <i>Candida tropicalis</i>: An Emerging Threat to Immunocompromised Patients with Hematological MalignanciesMaroun M Sfeir, Cristina Jiménez-Ortigosa, Maria N Gamaletsou, et al.
Transplantation and Cellular Therapy|April 3, 2021
Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical ImplicationsJeffrey Kubiak, Emily Davidson, Rosemary Soave, et al.
Leukemia & Lymphoma|June 3, 2017
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>Sarah C Rutherford, Eric N Stewart, Zhengming Chen, et al.
Leukemia & Lymphoma|September 6, 2007
Successful allogeneic transplantation of patients with suspected prior invasive mold infectionBrian T Hill, Lavayna Kondapalli, Andrew Artz, et al.
Leukemia & Lymphoma|July 14, 2020
Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantationMaxwell Brown, Rza Abasov, David Salerno, et al.
Leukemia & Lymphoma|July 1, 2024
Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomesKoen van Besien, Hongtao Liu, Seunghee Margevicius, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantationAndrew S Artz, Amittha Wickrema, Shira Dinner, et al.
Cytotherapy|May 3, 2012
Influence of related donor age on outcomes after peripheral blood stem cell transplantationElie M Richa, Rangesh Kunnavakkam, Lucy A Godley, et al.
Pageof 25